Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is set to present new data on its tumor-infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, taking place November 6-10 in Houston, TX. The presentations will cover updated clinical results for lifileucel in combination with pembrolizumab in metastatic non-small cell lung cancer (NSCLC) and preclinical findings for IL12-engineered TIL therapy, IOV-5001.
Lifileucel Plus Pembrolizumab in Metastatic NSCLC
Updated results from a multicenter Phase 2 trial evaluating lifileucel in combination with pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC will be presented. This late-breaking abstract (#1488) highlights the potential of TIL therapy in combination with immune checkpoint inhibition to address the unmet needs of patients with advanced lung cancer. Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC accounting for approximately 85% of all lung cancer cases.
The study investigates the efficacy and safety of lifileucel, a personalized TIL therapy, when administered alongside pembrolizumab, an anti-PD-1 antibody. The combination aims to enhance the anti-tumor immune response in patients who have not previously responded to checkpoint inhibitors. The presentation will provide insights into the clinical benefits observed in this patient population.
Single-Cell Sequencing Analysis of Lifileucel TIL Products
Iovance will also present findings from a multimodal single-cell sequencing analysis of lifileucel TIL products (Abstract #409). This research delves into the composition and characteristics of TIL products, aiming to identify and understand the tumor-reactive populations within lifileucel. By employing advanced sequencing techniques, researchers have gained a deeper understanding of the mechanisms of action of lifileucel, potentially leading to improved patient selection and treatment strategies.
IL12-Engineered TIL Therapy: IOV-5001
Preclinical data on IOV-5001, an IL12-engineered TIL therapy, will be presented (Abstract #416). The data demonstrates superior anti-tumor activity of IOV-5001 in a simulated tumor microenvironment. This engineered TIL therapy is designed to enhance the persistence and activity of TIL cells within the tumor, potentially overcoming immunosuppressive mechanisms and improving treatment outcomes. Interleukin-12 (IL-12) is a cytokine known for its role in promoting T cell activation and anti-tumor immunity.
Iovance's presentations at SITC 2024 underscore the company's commitment to advancing TIL therapies for the treatment of solid tumors. These data presentations will provide valuable insights into the potential of lifileucel and next-generation TIL therapies to address unmet needs in cancer treatment.
